GlassScriptPhysician profile
Robert H Merz
NPI 1770580102
$2,627.11
in general payments reported to CMS, 2019-2025
32 companies · $440 in 2025
The $440 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,207 · 2020: $154 · 2021: $28.09 · 2022: $185 · 2023: $313 · 2024: $300 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $306.81 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $244.30 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $233.62 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $205.90 | 2019-2025 | |
| Cathworks, INC. | $151.52 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $147.26 | 2019-2023 | Eliquis |
| Boston Scientific Corporation | $143.74 | 2019-2025 | Bodyguardian |
| Kiniksa Pharmaceuticals, LTD. | $140.33 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $139.57 | 2019-2025 | Farxiga, Wainua |
| Akcea Therapeutics, INC. | $108.80 | 2019 | |
| Merck Sharp & Dohme LLC | $93.95 | 2024-2025 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $93.29 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.73 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.23 | 2021-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $40.24 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $39.14 | 2019-2023 | Evkeeza, Praluent |
| Irhythm Technologies, INC. | $37.64 | 2024 | Zio Monitor, Zio Xt Patch |
| Inspire Medical Systems, INC. | $32.50 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $30.48 | 2019 | |
| Impulse Dynamics (USA) INC. | $26.87 | 2024 | Optimizer |
| Sanofi Pasteur INC. | $26.26 | 2019 | |
| Esperion Therapeutics, INC. | $24.96 | 2024 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $24.96 | 2019 | |
| Lundbeck LLC | $24.29 | 2019 | |
| Kestra Medical Technology Services, INC. | $21.47 | 2025 | Assure Wcd |
| Arbor Pharmaceuticals, INC. | $21.17 | 2019 | |
| Amarin Pharma, INC. | $19.83 | 2023 | |
| Sanofi-Aventis U.S. LLC | $18.74 | 2019 | |
| Bardy Diagnostics, INC. | $18.65 | 2020 | |
| Teleflex LLC | $17.79 | 2025 | Guideliner |
| Scpharmaceuticals INC. | $17.55 | 2023 | |
| Baxter Healthcare | $15.52 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Merz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.